On Oct. 6, 2021, AIM ImmunoTech released detailed safety data from a Phase 1 clinical study which supported the companyﾒs belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19.

The safety results showed that no severe adverse events were reported and found the drug to be generally well tolerated.